Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pain block could speed recovery after lung surgery

NCT ID NCT07512635

Symptom relief Sponsor: Sanming First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a long-acting numbing drug, liposomal bupivacaine, can improve recovery after lung surgery compared to the standard numbing drug. About 96 adults having lung surgery will receive one of the two drugs before surgery. The main goal is to see if the long-acting version leads to better recovery scores 24 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liposomal bupivacaine (Exparel)
What this could lead to
If it works, this could provide longer-lasting pain relief after lung surgery, helping patients recover faster and use fewer opioids.
What could go wrong
This is a small, early-phase trial with only 96 participants. The long-acting drug may not significantly improve recovery or could have side effects like any numbing medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients scheduled for thoracic surgery under general anesthesia via thoracoscopic approach; * Age 18-65 years; * Classified as Grade I-II by the American Society of Anesthesiologists (ASA). Exclusion Criteria: * History of local anesthetic allergy. * Chronic opioid users. * Contraindications for nerve block, including infection at the puncture site and coagulation disorders; * Language communication impairment. * Other conditions unsuitable for inclusion in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liposomal bupivacaine are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liposomal bupivacaine Pulmonary nodule

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • SanMing First Hospital

    RECRUITING

    Sanming, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.